Author page: Kathrin Folkendt

Amber Therapeutics Secures $100M Series A Funding for Neuromodulation Therapy for Mixed Urinary Incontinence

Amber Therapeutics, a UK-based medical technology company, has successfully closed a $100 million Series A financing round. The investment will advance their Amber-UI neuromodulation therapy towards US FDA approval. The financing round, one of the largest ever in Europe for a medical technology company, was led by New Enterprise Associates (NEA) with participation from F-Prime Capital, Lightstone Ventures, Intuitive Ventures, and existing…

Wisp Expands into Fertility; Enhancing Access to Comprehensive Reproductive Care

Wisp, a company working in sexual and reproductive health, has taken a step forward by launching a new fertility vertical aimed at supporting women through every stage of their reproductive health journey. Through this strategic move Wisp wants to make healthcare more affordable and accessible for women, especially those facing challenges in conceiving. Fertility is a crucial aspect of women’s reproductive health,…

Women’s Health Research Round-up (June 10, 2024)

In recent years, there has been a significant increase in research focusing on women’s health, addressing various conditions, and exploring innovative solutions to improve health outcomes. This round-up article presents an overview of the latest studies and their contributions to understanding and advancing women’s health. This round-up was created with help from our very own Femtech Bot. We welcome your feedback on content…

Women’s Health Research Round-up (June 3, 2024)

In recent years, there has been an increase in research focusing on women’s health, addressing various conditions, and exploring innovative solutions to improve health outcomes. This round-up article presents an overview of the latest studies published last week and their contributions to understanding and advancing women’s health. From understanding structural changes needed at the NIH to exploring the impact of social isolation…

Natural Cycles Secures $55 Million Series C Funding to Accelerate Growth Ahead of Possible IPO

Natural Cycles, a women’s health company known for developing the world’s first birth control app, has announced the successful closure of its $55 million Series C financing round. The round was led by Lauxera Capital Partners, with additional participation from Point72 Private Investments and a revolving debt facility provided by J.P. Morgan. Natural Cycles, co-founded in 2013 by Dr. Elina Berglund Scherwitzl…

Gameto Secures $33M in Series B Funding to Advance Novel In Vitro Fertilization Treatments

Gameto, a biotech firm dedicated to women’s health, has announced the successful closure of a $33 million Series B financing round. This round, which exceeded initial targets, was led by Two Sigma Ventures and RA Capital, with participation from existing investors such as Insight Partners, Future Ventures, and BOLD Capital Partners. New investors include Olivia Walton’s Ingeborg Investments, Stacey Bendet Eisner, and…

Seek Launches First At-Home Test for Alcohol’s Effects on Women’s Health

Healthtech startup Seek has launched the first at-home lab test specifically designed to measure the impact of alcohol on women’s health. Founder Katie Garry’s inspiration for Seek stemmed from personal experiences. Recognizing the lack of resources for women who want to continue drinking while taking care of their health, Seek aims to fill this void by offering a test that measures biomarkers…

What’s New in Femtech This Week? (May 23, 2024)

Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page. Highlights Amplexd Therapeutics secures $2M to advance HPV-induced cervical precancer treatments. Estonian maternity startups CARA Health secures €620K for German expansion. Hinge Health adds movement-based menopause support to…